AMG 334 20160172 Pediatric Migraine PK Study.

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 4, 2018

Primary Completion Date

November 23, 2021

Study Completion Date

November 23, 2021

Conditions
Migraine
Interventions
DRUG

AMG 334 Dose 1

"Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.~Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2"

DRUG

AMG 334 Dose 2

Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.

DRUG

AMG 334 Dose 3

Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.

Trial Locations (14)

13210

State University of New York Upstate Medical University, Syracuse

14226

Dent Neurosciences Research Center, Amherst

30328

PANDA Neurology and Atlanta Headache Specialists, Atlanta

33407

Premiere Research Institute, West Palm Beach

34208

Synergy Health, Bradenton

43205

Nationwide Childrens Hospital, Columbus

45229

Cincinnati Childrens Hospital Medical Center, Cincinnati

46202

Riley Hosptial, Indianapolis

55441

Clinical Research Institute Inc, Plymouth

64108

Childrens Mercy Hospital, Kansas City

68901

Meridian Clinical Research, Hastings

72202

Arkansas Childrens Hospital, Little Rock

80112

CarePoint, Englewood

06905

New England Institute for Clinical Research, Stamford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY